What does license — proceeds from collaborators mean?

This metric captures cash inflows received from strategic partners or collaborators related to joint development or commercialization efforts. It serves as a key indicator of the value proposition of the company's drug pipeline to external industry players. High proceeds suggest strong external validation of the company's research and development assets.

Lexicon Pharmaceuticals LXRX License — Proceeds from collaborators

Similar metrics at other companies

ABUSCollaborations and licenses — Revenue

$204K-84.5%

VIRLicense and collaboration revenue — Total revenues

-$41K+41.4%

STOKLicense — Revenue

$2.88M-60.9%

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

TVTXLicense and collaboration revenue — Total Revenue

$2.71M-54.1%

TGTXLicense — Revenue

$3.61M+201%

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$986.12M+262%

Enterprise value$976.73M+209%

P/S14.2×+5.4×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromCollaborators.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's license — proceeds from collaborators.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's license — proceeds from collaborators?: Lexicon Pharmaceuticals (LXRX) reported license — proceeds from collaborators of $10M in Q1 2026.
What does license — proceeds from collaborators mean?: This metric captures cash inflows received from strategic partners or collaborators related to joint development or commercialization efforts. It serves as a key indicator of the value proposition of the company's drug pipeline to external industry players. High proceeds suggest strong external validation of the company's research and development assets.